Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Pimavanserin for the Treatment of Schizophrenia
2016-003434-24Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Adjunctive pimavanserin with Adjunctive placebo (2 arms). Primary endpoint: Change from Baseline to Week 6 in PANSS total score. Started Feb 2017; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-003434-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003434-24.